Equities research analysts expect Acceleron Pharma Inc (NASDAQ:XLRN) to post earnings of ($0.24) per share for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Acceleron Pharma’s earnings, with the lowest EPS estimate coming in at ($0.35) and the highest estimate coming in at ($0.11). Acceleron Pharma posted earnings of ($0.63) per share in the same quarter last year, which would indicate a positive year over year growth rate of 61.9%. The business is expected to issue its next earnings results on Thursday, August 1st.

On average, analysts expect that Acceleron Pharma will report full year earnings of ($2.44) per share for the current fiscal year, with EPS estimates ranging from ($2.78) to ($1.98). For the next financial year, analysts forecast that the business will post earnings of ($1.40) per share, with EPS estimates ranging from ($1.60) to ($1.17). Zacks’ EPS averages are an average based on a survey of research analysts that follow Acceleron Pharma.

Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.07). The firm had revenue of $2.78 million for the quarter, compared to analyst estimates of $3.67 million. Acceleron Pharma had a negative net margin of 965.39% and a negative return on equity of 35.94%. Acceleron Pharma’s revenue for the quarter was down 13.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.58) EPS.

XLRN has been the subject of a number of research reports. BidaskClub cut Xencor from a “sell” rating to a “strong sell” rating in a research report on Tuesday, June 11th. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Tuesday, June 4th. Zacks Investment Research reissued a “sell” rating on shares of ZALANDO SE/ADR in a research report on Sunday, June 30th. Goldman Sachs Group raised Koninklijke KPN from a “neutral” rating to a “buy” rating in a research report on Wednesday, May 29th. Finally, Barclays set a $24.00 price objective on Orion Engineered Carbons and gave the company a “hold” rating in a research report on Friday, May 3rd. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $59.44.

XLRN opened at $41.09 on Thursday. The firm has a market capitalization of $2.19 billion, a PE ratio of -15.86 and a beta of 1.21. Acceleron Pharma has a 1 year low of $37.01 and a 1 year high of $59.59. The company has a current ratio of 19.26, a quick ratio of 19.26 and a debt-to-equity ratio of 0.05. The company’s fifty day moving average price is $40.55.

In related news, Director Joseph S. Zakrzewski purchased 5,000 shares of Acceleron Pharma stock in a transaction on Friday, June 14th. The stock was bought at an average price of $38.05 per share, with a total value of $190,250.00. Following the completion of the transaction, the director now directly owns 12,750 shares of the company’s stock, valued at $485,137.50. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jean George sold 37,500 shares of the business’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $39.79, for a total value of $1,492,125.00. Following the completion of the sale, the director now directly owns 23,750 shares of the company’s stock, valued at approximately $945,012.50. The disclosure for this sale can be found here. 2.50% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in XLRN. FMR LLC increased its stake in shares of Acceleron Pharma by 6.3% in the first quarter. FMR LLC now owns 7,363,953 shares of the biopharmaceutical company’s stock worth $342,939,000 after purchasing an additional 435,414 shares during the period. BlackRock Inc. increased its stake in shares of Acceleron Pharma by 1.9% in the fourth quarter. BlackRock Inc. now owns 4,428,894 shares of the biopharmaceutical company’s stock worth $192,880,000 after purchasing an additional 81,002 shares during the period. Westfield Capital Management Co. LP increased its stake in shares of Acceleron Pharma by 6.5% in the first quarter. Westfield Capital Management Co. LP now owns 1,377,123 shares of the biopharmaceutical company’s stock worth $64,133,000 after purchasing an additional 84,410 shares during the period. Janus Henderson Group PLC increased its stake in shares of Acceleron Pharma by 2.7% in the first quarter. Janus Henderson Group PLC now owns 1,310,533 shares of the biopharmaceutical company’s stock worth $61,031,000 after purchasing an additional 34,346 shares during the period. Finally, Great Point Partners LLC increased its stake in shares of Acceleron Pharma by 12.9% in the fourth quarter. Great Point Partners LLC now owns 1,036,575 shares of the biopharmaceutical company’s stock worth $45,143,000 after purchasing an additional 118,808 shares during the period. 92.54% of the stock is owned by institutional investors.

Acceleron Pharma Company Profile

Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.

Featured Article: How to Invest in the Dividend Aristocrat Index

Get a free copy of the Zacks research report on Acceleron Pharma (XLRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.